Icariin inhibits MMP‑1, MMP‑3 and MMP‑13 expression through MAPK pathways in IL‑1β‑stimulated SW1353 chondrosarcoma...

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease causing significant disability and socioeconomic burden.
• Current OA therapies primarily manage symptoms, highlighting the need for novel agents that target disease-modifying processes.
• Matrix metalloproteinases (MMPs) are implicated in cartilage degradation in OA, making them therapeutic targets.

Purpose of the Study:

• To investigate the effects of Icariin on the expression of MMP-1, MMP-3, and MMP-13 in human chondrosarcoma cells stimulated with interleukin-1β (IL-1β).
• To elucidate the underlying mechanisms of Icariin's chondroprotective effects, focusing on mitogen-activated protein kinase (MAPK) signaling pathways.
• To assess Icariin's impact on key signaling molecules including phosphorylated p38, JNK, and ERK.

Main Methods:

• Human SW1353 chondrosarcoma cells were treated with IL-1β to simulate the OA microenvironment.
• Cells were subsequently treated with Icariin, with or without MAPK pathway activators/inhibitors.
• Expression levels of MMPs, phosphorylated p38, JNK, and ERK were quantified using RT-qPCR, ELISA, and Western blot analysis.

Main Results:

• Icariin significantly inhibited the expression of MMP-1, MMP-3, and MMP-13 in IL-1β-stimulated chondrocytes.
• Icariin treatment reduced the phosphorylation levels of p38, ERK, and JNK.
• Specific MAPK pathways were identified: p38 and ERK inhibition contributed to MMP-1/MMP-3 reduction, while p38 and JNK inhibition affected MMP-13 reduction.

Conclusions:

• Icariin demonstrates chondroprotective properties by inhibiting MMPs crucial for cartilage breakdown in osteoarthritis.
• The mechanism involves the modulation of MAPK signaling pathways, specifically p38, ERK, and JNK.
• Icariin shows potential as a novel therapeutic agent for osteoarthritis treatment.